Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk

详细信息    查看全文

• 作者：Hedi Schelleman ; Warren B. Bilker ; Colleen M. Brensinger ; Fei Wan ; Yu-Xiao Yang ; Sean Hennessy
• 关键词：Drug-drug interactions ; Pharmacoepidemiology
• 刊名：The American Journal of Medicine
• 出版年：2010
• 出版时间：February 2010
• 年：2010
• 卷：123
• 期：2
• 页码：151-157
• 全文大小：397 K

文摘

Purpose

To evaluate whether initiation of a fibrate or statin increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.

Methods

We used Medicaid claims data (1999-2003) to perform an observational case-control study nested within person-time exposed to warfarin in those ≥18 years (n = 353,489). Gastrointestinal bleeding cases were matched to 50 controls based on index date and state.

Results

Chronic warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of gemfibrozil (1.88; 95 % confidence interval [CI], 1.00-3.54] for the first prescription; 1.75; 95 % CI, 0.77-3.95 for the second prescription); simvastatin (1.46; 95 % CI, 1.03-2.07 for the first prescription; 1.60; 95 % CI, 1.07-2.39 for the second prescription); or atorvastatin (1.39; 95 % CI, 1.07-1.81 for the first prescription; 1.05; 95 % CI, 0.73-1.52 for the second prescription). In contrast, no increased risk was found with pravastatin initiation (0.75; 95 % CI, 0.39-1.46 for the first prescription; 0.90; 95 % CI, 0.43-1.91 for the second prescription).

Conclusions

Initiation of a fibrate or statin that inhibits CYP3A4 enzymes, including atorvastatin, was associated with an increased risk of hospitalization for gastrointestinal bleeding. Initiation of pravastatin, which is mainly excreted unchanged, was not associated with an increased risk.